Tīmeklis2024. gada 16. nov. · Sanofi Jan 2024 - Present2 years North Potomac, Maryland, United States • Lead a cross-functional team with the goal of obtaining regulatory/HTA approvals for Rezurock • Manage transplant study... Tīmeklis2024. gada 9. sept. · Sanofi’s acquisition of Kadmon Holdings adds Rezurock to its transplant portfolio in a deal worth $1.9bn. Just weeks after the surprise approval of …
Sanofi (SNY) to Buy Kadmon for $1.9B, Add cGVHD Drug Rezurock
Tīmeklis2024. gada 8. sept. · Sanofi is intent on investing more into its transplant operations through a $1.9 billion merger deal with Kadmon Holdings, another biopharma company that develops therapies for diseases with large unmet medical needs.. The acquisition expands Sanofi’s General Medicines core assets and highlights the addition of … Tīmeklis2024. gada 21. aug. · Any adolescent taking a proton pump inhibitor (PPI) or a strong CYP3A4 inducer will begin Cycle 1 Day 1 at the escalated dose of belumosudil 200 mg BID. Randomization will be stratified according to prior cGVHD treatment with ibrutinib (Yes / No) and severe cGVHD at baseline (Yes / No). professional glockenspiel for sale
FDA Approvals Roundup: Rezurock, Fexinidazole, Bylvay RAPS
Tīmeklis2024. gada 8. sept. · Sanofi SNY announced a definitive agreement to acquire New York-based biopharma company, Kadmon Holdings KDMN for $9.50 per share or a total equity value of $1.9 billion. The acquisition, if ... Tīmeklis2024. gada 8. sept. · Kadmon’s decade-long commitment to developing ROCK inhibitors has culminated in a $1.9 billion takeout by Sanofi, less than two months after the biotech’s first drug approval. The deal gives Sanofi (Euronext:SAN; NASDAQ:SNY) Rezurock belumosudil, a ROCK2 inhibitor that gained FDA’s approval on July 16 for … Tīmeklis2024. gada 1. dec. · Rezurock is indicated for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (chronic GVHD) … professional goals at work